Ortiz IFJ

Idioma: Español
Referencias bibliográficas: 7
Paginas: 263-265
Archivo PDF: 24.68 Kb.

FRAGMENTO

Desde la descripción del primer caso de infección por el virus de la inmunodeficiencia humana adquirido por la vía perinatal, en 1983, se vislumbró un panorama aterrador ante la evidencia de una nueva población en riesgo de SIDA: los niños.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Coonor EW, Sperling RS, Gelbert R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. NEJM 1994;331:1173-80.

2. CDC. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission. Thailand 1996- 1998. MMWR 1998;47-8:151-4.

3. International Perinatal HIV group. The mode of delivery and the risk of vertical transmission of human immunodefiency virus type 1. A meta-analysis of 15 prospective cohort studies. NEJM 1999;340:77-987.

4. Moodley J, Moodley K, Pillay H, et al. Pharmacokinetics andantiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodificiency virus type 1. Infected pregnant women and their offspring. JID 1998;178:1327-33.

5. Stiehm E, Lambert J, Mofenson L, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV. Infected women with advanced disease: Results of pediatric AIDS clinical trials group. Protocol 185. JID 1999;176:567-75.

6. Jackson B, Fleming T. A phase IIB, randomized, controlled trial to evaluated the safety, tolerance, and HIV vertical transmission rates associated with short course nevirapine (NVP) vs short course zidovudine (ZDV) in HIV infected pregnant women and their infants in Uganda. National Institute of Allergy and Infectious Diseases, July 12 ,1999.

7. Conference on Global Strategies for the prevention of the HIV transmission from mother to infant. Montreal, Canada, September 1-5,1999 (abstracts).